Cellectar biosciences reports first quarter 2025 financial results and provides a corporate update

Company seeking conditional approval from european medicines agency (ema) for iopofosine i 131 in waldenstrom macroglobulinemia based upon clover wam phase 2 study data

CLRB Ratings Summary

CLRB Quant Ranking